Brokers Offer Predictions for ImmunityBio FY2027 Earnings

Key Points

• HC Wainwright raised its FY2027 EPS estimate for ImmunityBio to $0.05 (from -$0.01) and issued a Buy rating with a $10.00 price target, projecting further gains to $0.33 EPS in FY2028 and $0.55 in FY2029; this contrasts with the current consensus full-year estimate of ($0.92) per share.
• Analyst sentiment is skewed positive with five Buy ratings versus one Sell, an average price target of $11.80, and several firms (BTIG, Jefferies, Piper) recently raising their targets.
• Insiders own a large stake (reported at 69.48%) but have sold ~226,967 shares (~$1.53M) recently, while institutions like Vanguard increased holdings materially; the stock trades around $6.15 with a $6.06 billion market cap.

ImmunityBio, Inc. (NASDAQ:IBRX - Free Report) - Analysts at HC Wainwright boosted their FY2027 earnings estimates for ImmunityBio in a report issued on Monday, January 26th. HC Wainwright analyst A. Maldonado now expects that the company will earn $0.05 per share for the year, up from their prior forecast of ($0.01). HC Wainwright has a "Buy" rating and a $10.00 price target on the stock. The consensus estimate for ImmunityBio's current full-year earnings is ($0.92) per share. HC Wainwright also issued estimates for ImmunityBio's FY2028 earnings at $0.33 EPS and FY2029 earnings at $0.55 EPS.

ImmunityBio (NASDAQ:IBRX - Get Free Report) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.03. The business had revenue of $32.06 million for the quarter, compared to analysts' expectations of $31.88 million.

Several other equities research analysts have also recently issued reports on the stock. BTIG Research lifted their price objective on shares of ImmunityBio from $6.00 to $9.00 and gave the company a "buy" rating in a research report on Thursday, January 22nd. Jefferies Financial Group boosted their price target on shares of ImmunityBio from $8.00 to $9.00 and gave the stock a "buy" rating in a research note on Friday, December 12th. D. Boral Capital reissued a "buy" rating and set a $24.00 price objective on shares of ImmunityBio in a report on Tuesday, January 20th. Piper Sandler lifted their target price on ImmunityBio from $5.00 to $7.00 and gave the stock an "overweight" rating in a report on Tuesday, January 20th. Finally, Weiss Ratings reissued a "sell (e+)" rating on shares of ImmunityBio in a research note on Monday, December 29th. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $11.80.

ImmunityBio Price Performance

IBRX opened at $6.15 on Thursday. The company has a 50 day simple moving average of $2.98 and a two-hundred day simple moving average of $2.65. The firm has a market cap of $6.06 billion, a P/E ratio of -15.00 and a beta of 0.03. ImmunityBio has a 1-year low of $1.83 and a 1-year high of $8.28.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. grew its stake in shares of ImmunityBio by 26.8% during the 3rd quarter. Vanguard Group Inc. now owns 27,655,205 shares of the company's stock worth $68,032,000 after purchasing an additional 5,837,898 shares during the period. Armistice Capital LLC acquired a new stake in ImmunityBio during the second quarter valued at $20,497,000. Heights Capital Management Inc. purchased a new position in ImmunityBio in the third quarter valued at $16,152,000. Geode Capital Management LLC raised its position in shares of ImmunityBio by 34.7% in the second quarter. Geode Capital Management LLC now owns 5,777,269 shares of the company's stock worth $15,254,000 after acquiring an additional 1,487,849 shares during the period. Finally, Woodline Partners LP boosted its stake in shares of ImmunityBio by 53.7% during the 3rd quarter. Woodline Partners LP now owns 5,297,725 shares of the company's stock worth $13,032,000 after acquiring an additional 1,851,854 shares in the last quarter. Hedge funds and other institutional investors own 8.58% of the company's stock.

Insider Buying and Selling

In related news, Director Barry J. Simon sold 151,967 shares of the company's stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $7.20, for a total transaction of $1,094,162.40. Following the completion of the sale, the director directly owned 3,091,604 shares in the company, valued at $22,259,548.80. This represents a 4.69% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director Christobel Selecky sold 50,000 shares of the stock in a transaction that occurred on Friday, January 16th. The shares were sold at an average price of $5.00, for a total transaction of $250,000.00. The disclosure for this sale is available in the SEC filing. Insiders sold 226,967 shares of company stock valued at $1,531,912 in the last three months. 69.48% of the stock is currently owned by insiders.

ImmunityBio Company Profile

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.